Carbonic acid sodium salt (1:2) → 琥乙红霉素

HRID 1508608

反应方程式

HRID 1508608 反应方程式
[CH3:1][CH2:2][C@H:3]1[O:18][C:16](=[O:17])[C@H:15]([CH3:19])[C@@H:14]([O:20][C@@H:21]2[O:26][C@@H:25]([CH3:27])[C@H:24]([OH:28])[C@@:23]([O:30][CH3:31])([CH3:29])[CH2:22]2)[C@H:13]([CH3:32])[C@@H:12]([O:33][C@@H:34]2[O:39][C@H:38]([CH3:40])[CH2:37][C@H:36]([N:41]([CH3:43])[CH3:42])[C@H:35]2[OH:44])[C@@:11]([OH:46])([CH3:45])[CH2:10][C@@H:9]([CH3:47])[C:7](=[O:8])[C@H:6]([CH3:48])[C@@H:5]([OH:49])[C@@:4]1([OH:51])[CH3:50].C(=O)(O)[O-].[Na+].C(=O)([O-])[O-].[Na+].[Na+].C(=O)([O-])[O-].[K+].[K+].[Cl-].[C:70]([O:77][CH2:78][CH3:79])(=[O:76])[CH2:71][CH2:72][C:73]([O-])=[O:74].[Br-].C(OCC)(=O)CCC([O-])=O>CCOCC.O>[CH3:1][CH2:2][C@H:3]1[O:18][C:16](=[O:17])[C@H:15]([CH3:19])[C@@H:14]([O:20][C@@H:21]2[O:26][C@@H:25]([CH3:27])[C@H:24]([OH:28])[C@@:23]([O:30][CH3:31])([CH3:29])[CH2:22]2)[C@H:13]([CH3:32])[C@@H:12]([O:33][C@@H:34]2[O:39][C@H:38]([CH3:40])[CH2:37][C@H:36]([N:41]([CH3:42])[CH3:43])[C@H:35]2[O:44][C:73]([CH2:72][CH2:71][C:70]([O:77][CH2:78][CH3:79])=[O:76])=[O:74])[C@@:11]([OH:46])([CH3:45])[CH2:10][C@@H:9]([CH3:47])[C:7](=[O:8])[C@H:6]([CH3:48])[C@@H:5]([OH:49])[C@@:4]1([OH:51])[CH3:50]

参与物

9

反应物 6

HCID 10340Carbonic acid sodium salt (1:2)HCID 11430碳酸钾HCID 12560红霉素2 次HCID 516892碳酸氢钠HCID 18404837HCID 18404837，化合物HCID 86718268Monoethyl succinate bromide

产物 1

HCID 443953琥乙红霉素

试剂、催化剂与溶剂 2

HCID 962聚[6-[4-(4-氰基苯基)苯氧基]己基甲基丙烯酸酯]溶剂HCID 3283乙醚溶剂

反应条件

温度
25 °C

实验过程

The process for preparing erythromycin ethylsuccinate hydrate comprises: method A. in a reaction vessel, one or more of a C1-C6 lower alcohol, a C2-C6 lower nitrile, a C3-C8 lower ketone or C2-C8 lower ether is used as a solvent, to the solvent is added erythromycin, stirred at a temperature of 0-50° C. to dissolve erythromycin; to the solution is added sodium bicarbonate or sodium carbonate or potassium carbonate, and water, stirred, and cooled to 20° C. or below; to the cooled mixture is added monoethyl succinate halide, including monoethyl succinate chloride or monoethyl succinate bromide, allowed to react, and monitored by TLC until the reaction is complete; to the resultant is added an acid or a base to control the pH value at about 7.0-8.5; the organic phase is precipitated and separated; to the organic phase is added water, cooled to −20° C.-10° C.; upon the solid is precipitated completely, the mixture is filtered, the resulting solid is recrystalized with water and one or more of a C1-C6 lower alcohol, a C2-C6 lower nitrile, a C2-C8 lower ether, a C3-C8 lower ketone or C1-C6 lower halogenated hydrocarbons as solvent once or more times, cooled to −20° C.-10° C., filtered, dried to obtain erythromycin ethylsuccinate crystalline hydrate;

后处理

  1. stirringstirred
  2. temperaturecooled to 20° C. or below
  3. customto react
  4. additionto the resultant is added an acid
  5. customthe organic phase is precipitated
  6. customseparated
  7. additionto the organic phase is added water
  8. temperaturecooled to −20° C.-10° C.
  9. customupon the solid is precipitated completely
  10. filtrationthe mixture is filtered
  11. customthe resulting solid is recrystalized with water and one or more of a C1-C6 lower alcohol
  12. temperaturea C2-C6 lower nitrile, a C2-C8 lower ether, a C3-C8 lower ketone or C1-C6 lower halogenated hydrocarbons as solvent once or more times, cooled to −20° C.-10° C.
  13. filtrationfiltered
  14. customdried

来源与证据

ORD记录
ord-75738953660c40d2a5f43ae562378a52
来源数据集
uspto-grants-2015_12
专利号
US09221862B2

关联笔记

加载中…